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ORIGINAL ARTICLE
Gastrointestinal stromal tumors (GISTs) are the
most common mesenchymal tumors of the gas-
trointestinal tract. They are believed to arise from
interstitial cells of Cajal (i.e. pacemaker cells).1
The annual incidence of GIST is estimated at
0.68–1.45 per 100,000. The tumors occur typi-
cally in older individuals and arise most often 
in the stomach, followed by the small intestine,
colon, rectum and esophagus.2,3 Central to the
tumorigenesis of GISTs are active mutations in
the proto-oncogene tyrosine-protein kinase (KIT)
or platelet-derived growth factor receptor alpha
(PDGFRA) gene, with a detection rate of 60–80%
and 3–7%, respectively.4,5 These mutations have
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been identified as alternative and mutually exclu-
sive genetic events in GIST development, which
target seemingly similar downstream pathways.6,7
Surgery is the mainstay of treatment, but even
after adequate resection, the vast majority of
GISTs recur, and in approximately 50% of cases,
the liver is the main site of metastasis.8,9 A small
number of patients survive intra-abdominal me-
tastasis for up to 20 years. However, patients with
tumors that have metastasized at presentation
have a very poor prognosis.10 The recurrent or
advanced tumors are resistant to radiotherapy
and chemotherapy, and have had an extremely
poor prognosis in the past.11 Recently, the in-
troduction of imatinib mesylate (trade names
Glivec, Gleevec; Novartis, Basel, Switzerland) has
greatly altered the clinical course of patients with
advanced GIST.12,13 Its effectiveness depends on
the mutational status of KIT and PDGFRA.
Approximately 80% of these patients have a par-
tial response or stable disease. However, acquired
resistance is a further clinical challenge, and can
develop in half of the patients who initially 
benefit from the drug.14,15
The criteria delineating benign from malig-
nant tumors have not been established reliably.
Tumor size, mitotic index, and anatomic site are
often used to predict disease-specific survival in
patients with primary disease who undergo com-
plete gross resection.16,17 However, a small subset
of small and/or mitotically inactive tumors does
metastasize subsequently.2,18 Many other prog-
nostic markers have also been reported, with vari-
able significance, including patterns of KIT and
PDGFRA mutations.7 Apparently, the lack of a 
reliable method of prognostication hampers the
selection of patients eligible for imatinib mesy-
late therapy, a critical step for avoiding waste of
resources and possible lack of responsiveness,
particularly with the progress of adjuvant and
neoadjuvant clinical trials.
Although KIT and PDGFRA mutations play 
a fundamental role in early GIST carcinogenesis,
other molecular mechanisms appear to be neces-
sary in tumor progression. Cytogenetic alterations
have been proposed to act as a complementary
mechanism of GIST development, with accumu-
lation of chromosomal imbalances (CIs) in con-
junction with disease progression.19–31 Some CIs
have been suggested to play a prognostic role in
this disease, but have revealed a conflicting sig-
nificance among different studies. For example,
some authors have linked losses at 1p and 22q 
to malignant behavior in GISTs,21,28–31 whereas
others have not identified these aberrations as
carrying prognostic value.22,26
Although gastric and intestinal GISTs are 
cytogenetically related, recent studies have re-
vealed consistently that there are substantial site-
dependent, genetic differences.20–23 Evaluation
of the prognostic role of the CIs in GISTs thus
needs to be examined on a site-specific basis.
Moreover, because of the heterogeneous nature
of malignant tumors, the CIs of a minor but 
aggressive tumor component that leads to metas-
tasis can often be overlooked in the analysis of
primary tumors using comparative genomic hy-
bridization (CGH). To avoid this pitfall, we per-
formed CGH of 13 cases of surgically resected
liver metastatic GISTs, including seven derived
from the stomach and six from the small intestine.
Assessment of the CIs closely associated with
metastatic risk was made by comparing them
with the CGH findings of the 25 primary GISTs
reported in our previous study.23
Methods
Sample selection
In the pathological files at Chi Mei Medical
Center, most cases of metastatic GIST to the liver
were confirmed pathologically through needle
biopsy. The DNA isolated from serial microtome
sections of small paraffin-embedded tissue sam-
ples theoretically contains a high proportion of
truncated nuclei, which may create a certain bias
in the CGH analysis. To avoid such a potential
pitfall, we collaborated with two other hospitals
in Taiwan to collect cases of surgically resected
liver metastatic GIST. A total of 13 cases were
found consecutively in the archive files of these
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hospitals between 1992 and 2004. All tumors 
included in this study were immunohistochemi-
cally positive for CD117. No patients had received
chemotherapy or radiotherapy prior to the surgical
resection.
Under the guide of the hematoxylin and eosin
stained section, the tumor tissue in the paraffin
block was selected for DNA preparation. The 
selected tissue was deparaffinized by treating it
twice with xylene at 55°C for 15 minutes each
time, followed by washes with absolute ethanol
and air-drying. The tissue was then incubated in
proteinase K solution (Sigma, St Louis, MO, USA)
with 0.5 mg/mL in 10 mM Tris, pH 7.8, 5 mM
EDTA, and 0.5% SDS, at 55°C overnight or
longer, if needed. DNA in suspension was puri-
fied using a phenol/chloroform procedure, and
resuspended in 1 × TE buffer.
CGH
The CGH procedure was modified from that de-
scribed by Kallioniemi et al,32 and is described in
detail elsewhere.23 Briefly, the metaphase slides
from normal females were kept in 95% ethanol
at −20°C for at least 48 hours before processing
for CGH. DNA from a tumor and genomic DNA
from an individual with normal karyotype (refer-
ence DNA) were directly labeled with fluorescein-
12-dUTP or Texas red-5-dUTP (NEN Life Science,
Boston, MA, USA), respectively, using the stan-
dard nick-translation procedure. After precipitat-
ing the DNA in the presence of Cot1 DNA (Gibco
BRL, Gaithersburg, MD, USA), the labeled DNA
mixture was hybridized to metaphase spreads on
a glass slide for 2–3 days. The slides were washed
and then counterstained with 4,6-diamidino-2-
phenylindole in an anti-fading solution.
Image acquisition, processing, and evaluation
were performed using a fluorescence microscope
(Olympus BX51, Tokyo, Japan) equipped with 
a Sensys charge-coupled device camera (Kodak
KAF 1400 chip; Photometrics, Tucson, AZ, USA),
which was controlled using the CytoVision im-
aging system (Applied Imaging, Santa Clara, CA,
USA). CIs were determined based on the cal-
culation of standard reference intervals using
CytoVision High-Resolution CGH software, by
which we stringently defined DNA losses or gains
as significant whenever the tumor profile and
the standard reference interval profile at 95%
confidence did not overlap.33 Short chromoso-
mal segments with a test-to-reference fluorescence
ratio > 1.5 were accepted as having high-level
amplification. In each experiment, a negative and
positive control with a known chromosomal gain
or loss was also included. The negative control
DNA was isolated from an individual with a nor-
mal karyotype. The positive control DNAs were
prepared from Epstein–Barr-virus-transformed
lymphoblastoid cell lines with either trisomy 21
(∼50 Mb) or an interstitial deletion of 2q23
(∼15 Mb).
For mathematical analyses, CIs were expressed
as losses, gains or high-level amplifications per
chromosomal arm. Assessment of the CIs with
high risk of metastasis was made by comparing
them with the CGH findings of the 25 primary
GISTs reported in our previous study.23 In the com-
parison between groups, we used Fisher’s exact
two-tailed test, the χ2 test, or the Mann–Whitney
U test. A value of p < 0.05 was considered statisti-
cally significant.
Results
As summarized in Table 1, the liver metastatic
GISTs were derived from the stomach of seven
patients (two female, five male), and from the
small intestine of six patients (two female, four
male). Patients’ age at the diagnosis of primary
GIST ranged from 38 to 70 years (female, 59–68
years; male, 38–70 years), with a mean of 58.8
years. Notably, synchronous detection of liver
metastasis at the initial diagnosis of the primary
GIST was more common in the cases of intes-
tinal origin (5/6, 83.3%) than in those of gastric
origin (2/7, 28.6%) (p = 0.048). The CGH results
disclosed that all liver metastases had a variable
number of CIs, involving 2–35 chromosomal
arms, as described in detail in Table 1. A detailed
description of the CIs of the primary gastric
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(n = 14) and intestinal (n = 11) GISTs reported 
in our previous study23 can be found in the
Progenetix database at http://130.60.44.174/
progenetix/P14730211/.
For the gastric group, the liver metastatic tumors
(n = 7) had CIs that involved 6–39 chromosomal
arms, with gains more prevalent than deletions.
The average number of chromosomal arms with
gain and deletions were 11.1 and 7.3, respectively.
However, the primary tumors (n = 14) reported
in our previous study23 had more deletions than
gains, with gains and deletions involving an 
Table 1. CIs detected in 13 liver metastatic GISTs using comparative genomic hybridization
Case Sex Age at Pri Dx of Mets* CIs
From stomach
1 M 38 38 +1q, +2pter-q12, +2q21-qter, −3p13-p24, −3q12-q24, +5 (5q21-q23), 
−6p24-q25, −9, +12, −14q11-q31, +15, −16q11-q23, +17, +19, +20p, +21
2 F 59 59 −1p31-p36.1, +1q42-qter, −2q21, +3p12, −10p12-p13, 10q21-q22, 
15q13-q24, +18q23
3 M 54 55 (1) −1p33-pter, +1p13-p21, +7q, +8, −9pter-q33, −10p13-q25, −11p15-q13, 
−11q21-q24, −13, −14, −15, +16p12-p13.2, +20q, +21, −22 
4 M 69 70 (1) −9p13-p23, +11p12-pter (11p15), −15q12-q15, −16q12-q22, 
+17q21-qter (17q24-q25), −22
5 F 59 61 (2) −1p, +1q, +2p, +2q33-qter, +3p21, +3p24, +3q21-q23, +3q27-qter, +4p16,
+5p13.3, −5q, +6p21-p22, −6q11-q21, +6q24-qter, +7, +8p, +8q21, 
−9p21-pter, +9q22-qter (9q34), −10, +11p15, +11p11.2-q13, +11q23-qter, 
+12p13, +12q11-q13, +12q23-qter, +13q32-qter, −14q12-q31, −15q11-q25, 
+16, +17, +18p11.2, +18q23, +19, +20, +21q22, −22q12
6 M 70 73 (3) −1p21-pter, +3q27-qter, +4p14-pter, −9p13-p23, +12q24.3, −14q11-q31, 
+17q24-q25, −20p11.2-12, +21, −22
7 M 51 58 (7) −1p, +1q21-q24, +1q31-qter, +3p21, +5q31, −4p14-pter, −6p, −7q32-qter, 
+9q34, +10p11.2, +10q26, +11p11-q13, +11q23, +12p, −12q15-q24.2, 
−13, −14q21-q22, +16p11.2, +16q21-qter, +17p12-q21, +17q24-qter, 
+19p (19p13.2-13.3), −19q12, +20, +21, −22
From small intestine
8 M 48 48 −1p, +1q, −2p12-pter, +2q21-q36, +3p12, +3q24-qter, +5p, −7q11.2, 
9, +7q31, +8q, +11p11.2-q13, +11q24-qter, −12p13, −13, +12q24.3, 
−15q11-q25, +16q11.2, +17q11.2, −18q11.2-q21, +18q22-qter, +19q, 
+20, −22q13
9 M 54 54 −14q11.2-q24, −15q11.2-q25
10 F 60 60 −1p13-p33, +2q23, +3q26-qter, +6p21-p23, −6q, +7p22, +8p12-p21, 
+8q242-qter, +9q34, +10p13-pter, +11p15, +11q12-q13, −12p13, 
+12p11.2-q13, +12q24.1-qter, +14q31-q32, −15q11.2-q25, 
+16p13.1-pter, +16q21-qter, +17, −18q11.2-q22, +19, −21q21
11 M 65 65 −1p, +1q31, +3p12, +4p, +5p12-p13, −6, +7q, +12q11.2-q23, −13, −14, 
−15q14-qter, +16p11.2, −18q, +20, −21, −22
12 F 68 68 −1p31-pter, −6q21-q22, −15q15-q25, −18q21, −22
13 M 69 73 (4) −1p31-p34.2, +3p12, +4p12-p14, +4q21-q31.1, +5p11-p14, −9q21-q22, 
+10p11.2, −11q13-q22, −15q14-q25, +16p11.2, +21q22
*Years between diagnosis of primary and metastatic GISTs in parentheses. Pri = primary GIST; Dx = diagnosis; Mets = metastatic GIST.
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average of 0.9 and 3.1 chromosomal arms, re-
spectively. The CIs detected in primary and liver
metastatic tumors are compared in Figure 1.
High-level amplification was not found in any of
the 14 primary tumors, but was detected in five
different sites in four samples of liver metastasis
(as underlined in Table 1 and indicated by broad
dark boxes in Figure 1).
With respect to the intestinal group, the liver
metastatic tumors (n = 6) had CIs that involved
2–26 chromosomal arms, with gains slightly
more common than deletions. The average num-
ber of chromosomal arms with gains and dele-
tions were 8.3 and 6.3, respectively. Similarly, 
for the primary tumors (n = 11) reported in our
previous study,23 gains were more common than
deletions, with gains and deletions involving an
average of 6.5 and 5.3 chromosomal arms, re-
spectively. The CIs detected in both primary and
liver metastatic tumors are compared in Figure 2.
No sample of primary or metastatic tumor
showed a chromosomal region with high-level
amplification.
Compared with the primary GISTs, the cumu-
lative CI profile of the liver metastases was very
similar to that of the intestinal group but not 
the gastric group (Figure 3). As indicated by the
dotted rectangle, 9p deletion seemed to be par-
ticularly more prevalent in the metastatic tumors
than in the primary intestinal GISTs. However,
from the detailed comparison of each group of
primary and metastatic GISTs (Table 2), it was
evident that 9p deletion was significantly more
prevalent in the metastatic tumor of the gastric
group than the intestinal group. Deletion of 14q
was the most common alteration in the primary
gastric GISTs, but did not become more preva-
lent in the metastatic lesions of either group.
Deletion of 22q, the second most common CI 
in the primary gastric GISTs, doubled in fre-
quency in the liver metastases of both groups,
with no significant difference. Deletions of 1p
and 15q were very common (> 80%) in both pri-
mary and metastatic tumors of the intestinal
group, and also exhibited a trend towards in-
crease in the metastatic tumors of the gastric
group. Most of the other common CIs listed in
Table 2 increased significantly in the liver metas-
tases of the gastric group but not the intestinal
group.





Figure 1. CGH profile of gastric GISTs, 
including 14 primary tumors (gray bars) 
and seven liver metastases (dark bars). Each
bar represents one tumor, with gains on the
right side and losses on the left side of the
ideogram of each chromosome. The broad 
dark boxes represent high-level amplification.
Discussion
The development and progression of cancer is
believed to involve a multistep genetic process,
with changes both at the molecular and cytoge-
netic level. While primary changes are important
for cellular transformation and tumor initiation,
secondary non-random changes accumulate at
later stages and are responsible for biological
tumor progression and dissemination.34 For
GISTs, mutually exclusive gain-of-function KIT
or PDGFRA mutations have been identified as
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Figure 2. CGH profile of intestinal GISTs, 
including 11 primary tumors (gray bars) and 
six liver metastases (dark bars). Each bar 
represents one tumor, with gains on the 
right side and losses on the left side of the
ideogram of each chromosome.
Figure 3. Comparison of the CGH profile of primary GISTs (including 14 from the stomach and 11 from the small intes-
tine) and liver metastases. The dark bars on the left side of each group indicate the relative frequency of deletion of the
corresponding chromosome arm, and the gray bars on the right side are frequencies of chromosomal gains.
primary steps in tumorigenesis. Rare variant KIT
or PDGFRA mutations have also been found in
association with anatomic site and distinct clini-
cal phenotype in selected GIST subsets.7 However,
the mutational status alone cannot fully explain
the diverse and apparently site-dependent biol-
ogy of these tumors. Other non-random genetic
changes identified at the cytogenetic level may
eventually complete the picture.
Gunawan et al22 and the authors of the pres-
ent study23 have described a site-dependent het-
erogeneous CI profile in GISTs, which has been
confirmed in a recent CGH analysis of 203 sam-
ples.20 Overall, deletion of 14q was more fre-
quent in gastric GISTs, while deletions of 1p, 6q,
13q, 15q and 22q and gain of 5p occurred more
often in intestinal tumors. Such site-dependent
heterogeneity of the CGH pattern does not relate
to tumor genotypes of KIT and PDGFRA genes.21
In the present analysis of 13 cases, we noticed
that liver metastases present at the initial diagno-
sis of the primary tumor was more common for
the intestinal group (83.3%, 5/6) than for the
gastric group (28.6%, 2/7) (p = 0.048). Moreover,
as depicted in Figure 3, we noticed that the 
CI profiles between primary intestinal and liver
metastatic tumors were very similar. Such an as-
sociation suggests that the CIs that are particu-
larly prevalent in the intestinal GISTs might be
closely associated with the intrinsic aggressive
characteristics of the intestinal GISTs.7,17
As shown in Table 2, the comparative results
disclosed that deletions 1p and 15q were very
common in primary and metastatic GISTs of in-
testinal origin, with detection frequencies rang-
ing from 82% to 100%. For the gastric group,
these alterations also showed a similar trend to-
wards an increase in the metastatic tumors. The
lack of statistical significance for the gastric group
was likely the result of the small sample size in
our study. However, when combined with the
CGH findings of another large study of primary
gastric GISTs (n = 116) reported by Gunawan 
et al,20 we noticed that these two alterations were
Y. Chen, et al
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Table 2. Comparison of the frequencies of common CIs between primary and liver metastatic GISTs of gastric and intestinal
origin*
Stomach Small intestine
Primary (n = 14) Liver metastasis (n = 7) p Primary (n = 11) Liver metastasis (n = 6) p
Gains
1q42-q44 0 4 (57) 0.002 4 (36) 1 (17) NS
12q24.3 0 3 (43) 0.008 4 (36) 2 (33) NS
17p11.2-p12 1 (7) 3 (43) MS 2 (18) 1 (17) NS
17q24-q25 1 (7) 5 (71) 0.002 4 (36) 1 (17) NS
19p13 1 (7) 3 (43) MS 3 (27) 1 (17) NS
20p12 0 3 (43) 0.008 1 (9) 2 (33) NS
20q13.1 0 3 (43) 0.008 5 (45) 2 (33) NS
21q22 0 5 (71) < 0.001 1 (9) 1 (17) NS
Deletions
1p32-p34 5 (36) 5 (71) NS 11 (100) 5 (83) NS
9p21-p23 2 (14) 5 (71) 0.009 0 1 (17) NS
10p12-p13 0 3 (43) 0.008 1 (9) 0 NS
10q21-q22 0 3 (43) 0.008 2 (18) 0 NS
13q 0 2 (29) MS 4 (36) 2 (33) NS
14q 11 (78) 5 (71) NS 6 (55) 2 (33) NS
15q 2 (14) 4 (57) MS 9 (82) 6 (100) NS
22q 5 (36) 5 (71) NS 3 (27) 3 (50) NS
*Data presented as n (%). NS = no statistical significance; MS = marginal statistical significance, with p ranging from 0.035 to 0.049 (Fisher’s exact test).
significantly more prevalent in the liver metas-
tases than in the primary tumors of gastric ori-
gin, with p = 0.003 for 1p deletion (5/7 vs. 25/116)
and p < 0.001 for 15q deletion (4/7 vs. 9/116).
These findings indicate that deletions of 1p and
15q play an important role in the acquisition of
aggressiveness in the early stage of tumorigenesis
of intestinal GISTs. To the best of our knowledge,
the genes residing on 1p and 15q have not yet
been fully elucidated as potential candidates. An
interesting tumor-associated gene that maps to
1p36 is ENO1, also known as MYC promoter-
binding protein 1. The binding of ENO1 represses
MYC expression and prevents the stimulation of
cell proliferation.35
In the GISTs of gastric origin, the most com-
mon CI is 14q deletion, which showed a similar
frequency in the primary tumors (78%) and liver
metastases (71%). However, as depicted in Table
2, the alteration was present in only 55% (6/11)
and 33% (2/6), respectively, of the primary and
metastatic GISTs of intestinal origin. Hence, it is
unlikely to be associated with metastatic risk of
this disease. The next most prevalent CIs of pri-
mary gastric GISTs are deletions of 1p (36%),
which had doubled to 71% in liver metastases.
Compared with tumors of intestinal origin, in
contrast to 1p deletion with high prevalence, 22q
deletion also doubled from 27% to 50% in the
liver metastases at a relatively low rate. These
findings seemingly imply that 22q deletion also
plays a role, with less critical significance, in the
acquisition of aggressiveness by GISTs. This alter-
ation has been reported in association with high-
risk GISTs previously, including by our own
group,20,23,28,30 but was not seen in another pre-
vious study.26 Recently, Gunawan et al,20 based
on CGH analysis and long-term follow-up, pro-
posed three major cytogenetic pathways in GISTs,
one initiated by 14q deletion, one by 1p dele-
tion, and another by 22q deletion. They indi-
cated that 22q deletion appears to initiate the
critical transition to an unfavorable cytogenetic
sub-pathway, by accumulating gain of 8q and
deletions of 9p and 9q. However, in the current
study of 13 liver metastases, eight samples had
22q deletion, including five and three of gastric
and intestinal origin, respectively. Only three
samples had gain of 8q and/or deletions of 9p
and 9q.
Another alteration worthy of note is 9p dele-
tion, which is one of the CIs commonly reported
in association with high-risk GISTs.26,30,36,37 In the
study of El-Rifai et al26 of clinically malignant
GISTs, the authors found that three of five liver
metastatic GISTs (of unknown primary origin)
had 9p deletion. In a microsatellite analysis of
GISTs, Sabah et al37 demonstrated that the loss
of heterozygosity at 9p21 was a common finding
in high-risk (malignant or recurrent) tumors, but
was absent in those of low malignant potential.
However, as shown in Table 2, we found that the
association between 9p deletion and liver metas-
tasis is significant only in the gastric group but
not in the intestinal group. Similarly, Schneider-
Stock et al38 found that a high predictive value
for p16INK4 (mapped to 9p21) alterations is
only significant in the group of benign and bor-
derline GISTs with regard to the clinical outcome.
Recently, in another much larger series of 284 pri-
mary GISTs,39 they further pointed out that loss
of p16INK4 seemed to identify a subgroup of
gastric GISTs with a worse prognosis (p = 0.037),
whereas it had no additional value for predicting
prognosis in intestinal GISTs.
As depicted in Table 2, some other CIs, includ-
ing deletions of 10p, 10q and 13q and gains of
1q, 12q, 17p + q, 19p, 20p + q and 21, were signif-
icantly more prevalent in liver metastases than in
primary tumors of gastric origin. Some of these,
including 10q deletion and gains of 17q and 20q,
have been found more frequently in high-risk
and/or clinically malignant GISTs in previous
studies.23,26 However, we did not discern a trend
towards similar increases of these CIs in the liver
metastases that arose from intestinal GISTs. There-
fore, it indicates that a role for these alterations for
the acquisition of aggressiveness during the early
stage of GIST progression is unlikely to be as criti-
cal as that of deletions of 1p, 15q, 22q and 9p.
In conclusion, among the common CIs, dele-
tions of 1q and 15q play an important role in 
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the acquisition of aggressiveness during the early
stage of GIST development. Deletion of 22q
plays a similar role with less critical significance.
Finally, 9p deletion is significant for the gastric
GISTs, but not in those arising from the small 
intestine.
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